From the Journals

Endocrine Society advises on diabetes care for older adults


 

FROM THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Managing complications

Hypertension is among the diabetes-related complications that need to be managed in older adults, and the guideline recommends a target blood pressure of 140/90 mm Hg, but other targets – based on patient-provider shared decision making – may be considered for patients in high-risk groups.

The guideline calls for management of hyperlipidemia with statin therapy and “use of an annual lipid profile to achieve the recommended levels for reducing absolute cardiovascular disease events and all-cause mortality.” The committee does not specify low-density lipoprotein cholesterol targets because of insufficient evidence, but recommends alternative treatments, including ezetimibe or proprotein convertase subtilisin/kexin type 9 inhibitors, if statin therapy is not enough to help the patients meet goals. The writers also advocate fish oil and/or fenofibrate for patients with fasting triglycerides of more than 500 mg/dL.

To manage congestive heart failure in older patients with diabetes, the guideline recommends following standard clinical practice guidelines for the condition, and cautious use of oral hypoglycemic agents, including glinides, rosiglitazone, pioglitazone, and dipeptidyl peptidase–4 inhibitors. The writers noted that low-dose aspirin is recommended for patients with diabetes with a history of atherosclerotic cardiovascular disease.

The committee also recommends an annual comprehensive eye exam for patients with diabetes aged 65 years and older to identify retinal disease and suggests that actions, such as physical therapy and reduced use of sedatives, be taken to minimize the risk of falls in patients with neuropathy or problems with balance and gait.

Older patients with diabetes also should be screened annually for chronic kidney disease, and the dosage of diabetes medications should be adjusted to minimize side effects in patients with kidney problems.

Tailoring care to setting

Finally, the guideline addresses special settings and populations, including managing diabetes in hospitals or nursing homes, or in patients who are transitioning to homes or long-term care facilities. Recommendations in this category include simplifying medications for older adults with terminal illness or severe comorbidities, as well as setting glycemic targets as part of a hospital discharge plan.

“The most important aspect of successful transition is effective, detailed, and thorough bidirectional communication between the discharging and receiving teams of health care providers,” the writers emphasized.

The guideline is cosponsored by the European Society of Endocrinology, the Gerontological Society of America, and the Obesity Society. The chair of the committee had no relevant financial conflicts to disclose, and at least 50% of the committee members were free of relevant conflicts of interest.

SOURCE: LeRoith D et al. J Clin Endocrinol Metab. 2019;104:1520-74.

Pages

Recommended Reading

The costs and benefits of SGLT2 inhibitors & GLP-1 RAs
MDedge Endocrinology
Low-fat dairy associated with decreased risk of type 2 diabetes
MDedge Endocrinology
BMI screening trigger for type 2 diabetes is unreliable for at-risk black, Hispanic adults
MDedge Endocrinology
CARMELINA confirms linagliptin’s renal, CV safety, but it’s still third-line for type 2 diabetes
MDedge Endocrinology
FDA declines dapagliflozin indication as adjunct for type 1 diabetes
MDedge Endocrinology
Plant-based foods could keep type 2 diabetes at bay
MDedge Endocrinology
DECLARE-TIMI58 shows improved kidney function with dapagliflozin
MDedge Endocrinology
Inadequate glycemic control in type 1 diabetes leads to increased fracture risk
MDedge Endocrinology
FDA approves Baqsimi nasal powder for emergency hypoglycemia treatment
MDedge Endocrinology
No increase in UTI risk with SGLT-2 inhibitors
MDedge Endocrinology